Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Pediatr Blood Cancer ; 71(2): e30792, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38053237

RESUMO

BACKGROUND/OBJECTIVES: High-risk Hodgkin lymphoma (HRHL) in children is curable with combined modality therapy. The Association of Pediatric Hematology-Oncology of Central America (AHOPCA) is a consortium of cancer centers from Central America. In 2004, AHOPCA implemented a guideline with a short course of chemotherapy (mStanfordV), strict diagnostics, and radiation guidelines, aimed at reducing abandonment and improving outcomes. METHODS: Newly diagnosed children less than 18 years of age with high-risk HL (Ann Arbor stages: IIB, IIIB, IV) from AHOPCA centers were staged with chest radiography and ultrasound or computed tomography. Therapy was a modified Stanford V (mStanfordV), substituting cyclophosphamide for mechlorethamine and involved field radiation. RESULTS: Of 219 patients with HRHL, 181 patients were eligible and evaluable; 146 (81%) were boys, 22% being less than 6 years; 43 were stage IIB, 84 IIIB, and 54 IV. Thirty-one (17%) abandoned therapy, 28 (15%) progressed, 30 (17%) relapsed, and eight (4%) died of toxicity. Radiation guidelines were not followed. Five-year abandonment-sensitive event-free survival and overall survival (AS-EFS, AS-OS ± SE) for the cohort were 46% ± 4% and 56% ± 4%; 5-year AS-OS for stages IIB, IIIB, and IV was 76% ± 7%, 59% ± 7%, and 35% ± 7% (p = .0006). CONCLUSION: Despite instituting a short treatment guideline, it did not improve the abandonment rate (17%) and did not achieve the reported outcomes of Stanford V. The cyclophosphamide dose used to replace merchlorethamine was inadequate. Despite strict guidelines, the radiation therapy application was inaccurate. Weekly chemotherapy may have adversely affected abandonment of therapy by increasing the burden of travel time. Based on these results, AHOPCA established a new abandonment strategy and a new guideline.


Assuntos
Antineoplásicos , Doença de Hodgkin , Masculino , Criança , Humanos , Feminino , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/patologia , Vincristina , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Antineoplásicos/uso terapêutico , Ciclofosfamida , Resultado do Tratamento , Doxorrubicina
2.
Pediatr Blood Cancer ; 66(5): e27621, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30677231

RESUMO

BACKGROUND: Treating B-non-Hodgkin lymphoma (B-NHL) in lower-income countries is challenging because of imprecise diagnosis, the increased risk of fatal toxicity associated with advanced disease at presentation, and limited supportive care. PROCEDURE: Central American patients with newly diagnosed stage I or II B-NHL received a modified Berlin-Frankfurt-Münster (BFM) regimen including a prephase (prednisone, cyclophosphamide) followed by A/B/A courses (A: cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate, and intrathecal therapy; B: cyclophosphamide, dexamethasone, doxorubicin, methotrexate, and intrathecal therapy). Those with stage III or IV NHL received additional courses (B/A/B), intensified for stage IV disease by additional vincristine and methotrexate doses. Patients in poor condition received a second prephase treatment before their chemotherapy courses. RESULTS: Between March 2004 and June 2016, of 405 patients with B-NHL, 386 (109 females) were eligible for treatment. Immunohistochemistry was performed in 177 cases (47.4%) and characterized the disease as mature B-cell lymphoma. Stage distribution was as follows: I/II, 31 (8.1%); III, 252 (65.3%); IV, 93 (24.1%); 10 (2.6%) not available. The 3-year overall survival was 70% for the whole group (86% for stages I/II, 75% for stage III, 58% for stage IV). Events included death during induction (34 patients, 8.8%), relapse/progression (46, 11.9%), death in remission (9, 2.3%), second malignancy (1, 0.26%), and death of unknown cause (1, 0.26%). Twenty-three (6%) patients abandoned or refused therapy. CONCLUSIONS: Approximately 70% of children with B-NHL from Central America experienced long-term, disease-free survival with a modified BFM schedule. Toxic death and relapse/resistant disease were the main reasons for treatment failure.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/mortalidade , Adolescente , América Central , Criança , Pré-Escolar , Feminino , Seguimentos , Hematologia , Humanos , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/patologia , Masculino , Prognóstico , Taxa de Sobrevida
3.
Rev. méd. hondur ; 60(4): 155-9, oct.-dic 1992. tab
Artigo em Espanhol | LILACS | ID: lil-126394

RESUMO

Se realizó un estudio descriptivo, transversal y de prevalencia para la deteminación de la frecuencia de la hemoglobinopatía "S" (Hb S) en la población de raza negra que acudió al Hospital Paredes de Trujillo, Colón, de Septiembre de 1990 a Marzo de 1991. Se muestrearon a un total de 829 pacientes de dicha raza distribuidos de la siguiente manera: 266 (32.09//) correspondieron al sexo masculino y 563 (67.91//) al sexo femenino; El mayor porcentaje de pacientes estudiados estaba comprendido entre los 1 y los 29 años de edad con 648 (78.17//) muestras. A todas las muestras se les practicó la prueba de inducción de drepanocitos con metabisulfito de sodio encontrándose un total de 69 (8.32//) muestras positivas a las cuales posteriormente se les realizaron hemolizados con tolueno y luego la prueba de electroforesis de hemoglobina en acetato de celulosa. De las 69 muestras, 54(6.51//) presentaban alteraciones en sus patrones electroforéticos correspondiendo 44 (5.30//) a la hemoglobinopatía SA (HB SA), 9 (1.08//) a la hemoglobinopatía SS (Hb SS) y 1 (0.12//) a la hemoglobinopatía doble heterocigota SC (Hb SC). Los 15 casos restantes presentaron patrones electroforáticos normales


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Hemoglobina Falciforme/análise , Estudos Transversais , População Negra , Hemoglobinopatias , Anemia Falciforme/epidemiologia , Honduras
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA